hydroxychloroquine has been researched along with Overweight in 1 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wasko, MC | 1 |
| McClure, CK | 1 |
| Kelsey, SF | 1 |
| Huber, K | 1 |
| Orchard, T | 1 |
| Toledo, FG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes[NCT01326533] | Phase 4 | 32 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline in the disposition index (DI) (NCT01326533)
Timeframe: 13 weeks after baseline measurement
| Intervention | arbitrary units (Mean) |
|---|---|
| Hydroxychloroquine | 352 |
| Placebo | -218 |
Change from baseline in the insulin sensitivity index (Si) (NCT01326533)
Timeframe: 13 weeks after baseline measurement
| Intervention | 10^-4/pmol*l/min (Mean) |
|---|---|
| Hydroxychloroquine | 0.08 |
| Placebo | -0.11 |
1 trial available for hydroxychloroquine and Overweight
| Article | Year |
|---|---|
Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial.
Topics: Adult; Blood Glucose; Cytokines; Double-Blind Method; Female; Humans; Hydroxychloroquine; Insulin; I | 2015 |